Global HIV Therapeutics Market Analysis
HIV endemic has had devastating economic, social, health and psychological impacts over the years affecting millions of households in a significant manner over the last decade. Despite the concrete efforts from authorities and various philanthropic institutions, the numbers are still on an upward trend with a total of 33.3 Million HIV victims across the world till the end of 2009.
In such a scenario, the Highly Active Antiretroviral Therapy (HAART) has been very effective in reducing the number of HIV particles in the bloodstream, thus leading to a reduction in AIDS-related mortality. The market for this type of therapy has also expanded over time and reached to the mark of around US$ 12.6 Billion in 2010. Among all the key drugs in the market, multi-class combination product, Atripla dominates the HIV therapeutics market as products from other classes, such as NRTIs, NNRTIs, PIs, and Fusion Inhibitors are following the sales pattern. Our report has effectively analyzed the major marketed brands in the HIV therapeutics segment and presented a coherent research on the same.
A number of key HIV compounds are also in various phases of clinical trials being developed by companies like Gilead Sciences, Tibotec, etc. The HIV therapeutics market is attracting a huge amount of investment with majority of contribution coming from the public sector.
The report “Global HIV Therapeutics Market Analysis” analyzes the overall market size, and country level developments. It also provides the future landscape of global HIV therapeutics market which looks promising with the commercialization of new and innovative drugs. A brief description and recent activities of key market players have been included to show private sectors’ participation. Overall, the report is likely to provide intending clients with an effective insight into the global HIV therapeutics market.
In such a scenario, the Highly Active Antiretroviral Therapy (HAART) has been very effective in reducing the number of HIV particles in the bloodstream, thus leading to a reduction in AIDS-related mortality. The market for this type of therapy has also expanded over time and reached to the mark of around US$ 12.6 Billion in 2010. Among all the key drugs in the market, multi-class combination product, Atripla dominates the HIV therapeutics market as products from other classes, such as NRTIs, NNRTIs, PIs, and Fusion Inhibitors are following the sales pattern. Our report has effectively analyzed the major marketed brands in the HIV therapeutics segment and presented a coherent research on the same.
A number of key HIV compounds are also in various phases of clinical trials being developed by companies like Gilead Sciences, Tibotec, etc. The HIV therapeutics market is attracting a huge amount of investment with majority of contribution coming from the public sector.
The report “Global HIV Therapeutics Market Analysis” analyzes the overall market size, and country level developments. It also provides the future landscape of global HIV therapeutics market which looks promising with the commercialization of new and innovative drugs. A brief description and recent activities of key market players have been included to show private sectors’ participation. Overall, the report is likely to provide intending clients with an effective insight into the global HIV therapeutics market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. GLOBAL HIV/AIDS THERAPEUTICS MARKET OVERVIEW
3.1 Disease Overview
3.2 Market Overview
4. MAJOR MARKETED PRODUCTS
4.1 Atripla
4.2 Truvada
4.3 Kaletra
4.4 Reyataz
4.5 Fuzeon
4.6 Sustiva
5. COUNTRY-LEVEL ANALYSIS
5.1 US
5.2 Europe
5.3 Japan
5.4 India
6. PIPELINE ANALYSIS
7. RECENT DEVELOPMENTS
7.1 Drug Approvals
7.2 Licensing Agreements
8. INVESTMENT PATTERN
9. COMPETITIVE ASSESSMENT
9.1 Gilead Sciences, Inc
9.2 Bristol-Myers Squibb
9.3 GlaxoSmithKline
9.4 Abbott Laboratories
9.5 Pfizer
9.6 Merck
2. RESEARCH METHODOLOGY
3. GLOBAL HIV/AIDS THERAPEUTICS MARKET OVERVIEW
3.1 Disease Overview
3.2 Market Overview
4. MAJOR MARKETED PRODUCTS
4.1 Atripla
4.2 Truvada
4.3 Kaletra
4.4 Reyataz
4.5 Fuzeon
4.6 Sustiva
5. COUNTRY-LEVEL ANALYSIS
5.1 US
5.2 Europe
5.3 Japan
5.4 India
6. PIPELINE ANALYSIS
7. RECENT DEVELOPMENTS
7.1 Drug Approvals
7.2 Licensing Agreements
8. INVESTMENT PATTERN
9. COMPETITIVE ASSESSMENT
9.1 Gilead Sciences, Inc
9.2 Bristol-Myers Squibb
9.3 GlaxoSmithKline
9.4 Abbott Laboratories
9.5 Pfizer
9.6 Merck
LIST OF FIGURES
Figure 3-1: Global - Adult and Child Deaths due to AIDS (Million), 1990-2009
Figure 3-2: Global - Number of People Newly Infected with HIV (Million), 1990-2009
Figure 3-3: Global - HIV/AIDS Treatment Coverage in Low and Middle Income Countries (%), 2009
Figure 3-4: Global - HIV/AIDS Therapeutics Market (Billion US$), 2010-2014
Figure 4-1: Global - Atripla Sales (Billion US$), 2007-2010
Figure 4-2: Global - Truvada Sales (Billion US$), 2007-2010
Figure 4-3: Global - Kaletra Sales (Billion US$), 2007-2010
Figure 4-4: Global - Reyataz Sales (Billion US$), 2007-2010
Figure 4-5: Global - Fuzeon Sales (Million US$), 2009 & 2010
Figure 4-6: Global - Sustiva Sales (Billion US$), 2007-2010
Figure 5-1: US - Key HIV/AIDS Products Sales (Million US$), 2010
Figure 5-2: US - HIV/AIDS Therapeutics Market (Billion US$), 2010-2014
Figure 5-3: US - Federal Funding for HIV/AIDS (Billion US$), FY 2009 to FY 2012
Figure 5-4: US - Forecast for Federal Funding in HIV/AIDS by Category (%), FY 2012
Figure 5-5: EU - Number of AIDS Cases by Geographical Area (per ‘00,000 Population), 2004-2009
Figure 5-6: EU - HIV/AIDS Therapeutics Market (Billion US$), 2010-2014
Figure 5-7: Japan - Number of New HIV and AIDS Cases (1985-2008)
Figure 5-8: Japan - HIV/AIDS Therapeutics Market (Million US$), 2010-2014
Figure 5-9: Japan - Funding for HIV/AIDS by Category (%)
Figure 8-1: Global - HIV Spending in Low and Middle Income Countries (Billion US$), 2006-2008
Figure 8-2: Global - R&D Investment in HIV Treatment by Research Area (%), 2009
Figure 8-3: Global - Investment in HIV/AIDS Drug Discovery & Development by Area (%), 2009
Figure 8-4: Global - R&D Investment in HIV Treatment by Sector (%), 2009
Figure 9-1: GSK - Breakup of HIV/AIDS Product Sales (%), 2010
Figure 9-2: Merck - HIV/AIDS Drug Sales (Million US$), 2009 & 2010
Figure 3-1: Global - Adult and Child Deaths due to AIDS (Million), 1990-2009
Figure 3-2: Global - Number of People Newly Infected with HIV (Million), 1990-2009
Figure 3-3: Global - HIV/AIDS Treatment Coverage in Low and Middle Income Countries (%), 2009
Figure 3-4: Global - HIV/AIDS Therapeutics Market (Billion US$), 2010-2014
Figure 4-1: Global - Atripla Sales (Billion US$), 2007-2010
Figure 4-2: Global - Truvada Sales (Billion US$), 2007-2010
Figure 4-3: Global - Kaletra Sales (Billion US$), 2007-2010
Figure 4-4: Global - Reyataz Sales (Billion US$), 2007-2010
Figure 4-5: Global - Fuzeon Sales (Million US$), 2009 & 2010
Figure 4-6: Global - Sustiva Sales (Billion US$), 2007-2010
Figure 5-1: US - Key HIV/AIDS Products Sales (Million US$), 2010
Figure 5-2: US - HIV/AIDS Therapeutics Market (Billion US$), 2010-2014
Figure 5-3: US - Federal Funding for HIV/AIDS (Billion US$), FY 2009 to FY 2012
Figure 5-4: US - Forecast for Federal Funding in HIV/AIDS by Category (%), FY 2012
Figure 5-5: EU - Number of AIDS Cases by Geographical Area (per ‘00,000 Population), 2004-2009
Figure 5-6: EU - HIV/AIDS Therapeutics Market (Billion US$), 2010-2014
Figure 5-7: Japan - Number of New HIV and AIDS Cases (1985-2008)
Figure 5-8: Japan - HIV/AIDS Therapeutics Market (Million US$), 2010-2014
Figure 5-9: Japan - Funding for HIV/AIDS by Category (%)
Figure 8-1: Global - HIV Spending in Low and Middle Income Countries (Billion US$), 2006-2008
Figure 8-2: Global - R&D Investment in HIV Treatment by Research Area (%), 2009
Figure 8-3: Global - Investment in HIV/AIDS Drug Discovery & Development by Area (%), 2009
Figure 8-4: Global - R&D Investment in HIV Treatment by Sector (%), 2009
Figure 9-1: GSK - Breakup of HIV/AIDS Product Sales (%), 2010
Figure 9-2: Merck - HIV/AIDS Drug Sales (Million US$), 2009 & 2010
LIST OF TABLES
Table 3-1: Global - Key HIV/AIDS Statistics by Region (2001 & 2009)
Table 5-1: US - Key HIV/AIDS Statistics
Table 5-2: EU - Key HIV/AIDS Statistics by Geographical Area (2009)
Table 6-1: Global - Antiretroviral Compounds in Pipeline
Table 3-1: Global - Key HIV/AIDS Statistics by Region (2001 & 2009)
Table 5-1: US - Key HIV/AIDS Statistics
Table 5-2: EU - Key HIV/AIDS Statistics by Geographical Area (2009)
Table 6-1: Global - Antiretroviral Compounds in Pipeline
